ReviewJournal of clinical immunology2014
The case for mandatory newborn screening for severe combined immunodeficiency (SCID).
Review in Journal of clinical immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 66 citations in OpenAlex.
- Severe Combined Immunodeficiency-Classification, Microbiology Association and Treatment.Microorganisms · 2023Review
- Natural history of infants with non-SCID T cell lymphopenia identified on newborn screen.Clinical immunology (Orlando, Fla.) · 2022Article
- Severe Combined Immunodeficiency (SCID)-the Irish Experience.Journal of clinical immunology · 2021Article
- Modern diagnostic capabilities of neonatal screening for primary immunodeficiencies in newborns.Clinical and experimental pediatrics · 2021Article
- Colostrum from cows immunized with a veterinary vaccine against bovine rotavirus displays enhanced in vitro anti-human rotavirus activity.Journal of dairy science · 2019Article
- Simple Test, Complex System: Multifaceted Views of Newborn Screening Science, Technology, and Policy.Global pediatric health · 2019Article
- Short telomere syndromes cause a primary T cell immunodeficiency.The Journal of clinical investigation · 2018Article
- Advances in the Care of Primary Immunodeficiencies (PIDs): from Birth to Adulthood.Journal of clinical immunology · 2017Review
- Identification of 22q11.2 Deletion Syndrome via Newborn Screening for Severe Combined Immunodeficiency.Journal of clinical immunology · 2017Article
- FOXN1 deficient nude severe combined immunodeficiency.Orphanet journal of rare diseases · 2017Review
- Newborn Screening for Severe Primary Immunodeficiency Diseases in Sweden-a 2-Year Pilot TREC and KREC Screening Study.Journal of clinical immunology · 2017Article
- History and current status of newborn screening for severe combined immunodeficiency.Seminars in perinatology · 2015Review
- Primary immunodeficiencies screening: neonatal screening for T/B cell disorders - a triplex PCR method for quantitation of TRECs and KRECs in newborns.Clinical and experimental immunology · 2014Article
- Primary immune deficiencies - principles of care.Frontiers in immunology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe combined immunodeficiency (SCID) is the most severe form of inherited primary immunodeficiency and is a paediatric emergency. Delay in recognising and detecting SCID can have fatal consequences and also reduces the chances of a successful haematopoietic stem cell transplant (HSCT). Screening for SCID at birth would prevent children from dying before HSCT can be attempted and would increase the success of HSCT. There is strong evidence to show that SCID fulfills the internationally-established criteria for a condition to be screened for at birth. There is also a test (the T-cell receptor excision circle (TREC) assay) that is now being successfully used in an increasing number of US states to screen for SCID in routine newborn Guthrie samples. Concerted lobbying efforts have highlighted the need for newborn screening (NBS) for SCID, and its implementation is being discussed in Europe both at EU and individual country level, but as yet there is no global mandate to screen for this rare and frequently lethal condition. This paper summarizes the current evidence for, and the success of SCID NBS, together with a review of the practical aspects of SCID testing and the arguments in favour of adding SCID to the conditions screened for at birth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.